Evidence map›Paper›PMID 36139921›Full record

ReviewAntibiotics (Basel, Switzerland)2022

Use of Antibiotics in Preterm Newborns.

Raffaele Simeoli, Sara Cairoli, Nunzia Decembrino, Francesca Campi, Carlo Dionisi Vici, Alberto Corona, Bianca Maria Goffredo

Open access · goldAbstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Raffaele SimeoliDivision of Metabolic Diseases and Drug Biology, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy.ORCID 0000-0002-3989-7703
Sara CairoliDivision of Metabolic Diseases and Drug Biology, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy.ORCID 0000-0002-5925-0974
Nunzia DecembrinoNeonatal Intensive Care Unit, University Hospital "Policlinico-San Marco" Catania, Integrated Department for Maternal and Child's Health Protection, 95100 Catania, Italy.ORCID 0000-0001-6650-7881
Francesca CampiNeonatal Intensive Care Unit, Medical and Surgical Department of Fetus-Newborn-Infant, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Carlo Dionisi ViciDivision of Metabolic Diseases and Drug Biology, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy.
Alberto CoronaICU and Accident & Emergency Department, ASST Valcamonica, 25043 Breno, Italy.ORCID 0000-0003-2594-3278
Bianca Maria GoffredoDivision of Metabolic Diseases and Drug Biology, Bambino Gesù Children's Hospital, IRCCS, 00146 Rome, Italy.
Bambino Gesù Children's Hospital · ITPoliclinico Universitario di Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to complex maturational and physiological changes that characterize neonates and affect their response to pharmacological treatments, neonatal pharmacology is different from children and adults and deserves particular attention. Although preterms are usually considered part of the neonatal population, they have physiological and pharmacological hallmarks different from full-terms and, therefore, need specific considerations. Antibiotics are widely used among preterms. In fact, during their stay in neonatal intensive care units (NICUs), invasive procedures, including central catheters for parental nutrition and ventilators for respiratory support, are often sources of microbes and require antimicrobial treatments. Unfortunately, the majority of drugs administered to neonates are off-label due to the lack of clinical studies conducted on this special population. In fact, physiological and ethical concerns represent a huge limit in performing pharmacokinetic (PK) studies on these subjects, since they limit the number and volume of blood sampling. Therapeutic drug monitoring (TDM) is a useful tool that allows dose adjustments aiming to fit plasma concentrations within the therapeutic range and to reach specific drug target attainment. In this review of the last ten years' literature, we performed Pubmed research aiming to summarize the PK aspects for the most used antibiotics in preterms.

Indexed as

antibioticsmicro-samplingpharmacodynamicpharmacokineticpretermstherapeutic drug monitoring

Identifiers

PMID36139921
PMCPMC9495226
OpenAlexW4293162878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.